Skye Global Management’s Cardlytics CDLX Stock Holding History

Skye Global Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-220	Closed	-$241K	–	65
2021 Q1	$241K	Buy	+220	New	+$290K	﹤0.01%	62

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return

Skye Global Management's CDLX Position: Q2 2021 in Review

Skye Global Management sold out of Cardlytics (CDLX) in Q2 2021, closing a stake of 220 shares — an estimated $241K sold.

Skye Global Management first reported a position in CDLX in Q1 2021 and held it in 1 quarter. The position peaked at $241K in Q1 2021. 189 funds tracked by Wall St. Rank hold CDLX as of Q2 2021.

Skye Global Management reported no remaining Cardlytics position as of Q2 2021 after selling out during the quarter.
Skye Global Management sold 220 Cardlytics shares in Q2 2021, an estimated $241K.
Skye Global Management first reported a position in Cardlytics in Q1 2021 and held it in 1 quarter.
Skye Global Management's Cardlytics position peaked at $241K in Q1 2021.
189 funds tracked by Wall St. Rank held Cardlytics as of Q2 2021.

Based on Skye Global Management's 13F filing for Q2 2021, filed 16 Aug 2021.